Clozapine vs Iloperidone (Fanapt)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Clozapine
Marketed by HLS Therapeutics Inc.
NCT00250575 · Phase 3 · completed
The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.
Next expected readout: April 2027 · NCT04580134 (registry estimate)
Reported efficacy
Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. (mixed)
Result source: NCT03510325
Iloperidone (Fanapt)
Marketed by Vanda Pharmaceuticals
NCT00254202 · Phase 3 · completed
This 4-week, randomized, double-blind Phase 3 trial (Study 2 in the FANAPT label, n=604) compared iloperidone 24 mg/day with placebo and with ziprasidone as an active control in acute schizophrenia. The primary endpoint was change in PANSS total score at day 28. The FDA label states that iloperidone 24 mg/day was superior to placebo on this endpoint, so the primary was met; efficacy appeared similar to ziprasidone. Sources: CT.gov posted results and the FANAPT label (openFDA).
Next expected readout: November 2027 · NCT06961968 (registry estimate)
Reported efficacy
Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score (4 weeks): Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). (met)
Result source: NCT00254202
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Clozapine | Iloperidone (Fanapt) |
|---|---|---|
| PANSS total, change | —Not posted · NCT00649844 | -12 vs -7.1−4.9 vs placeboNCT002542021 other result
|
| CGI-S, change | —Not posted · NCT00649844 | —Trial running · NCT06961968 |
| PANSS response | —Not posted · NCT00649844 | —Trial running · NCT06961968 |
| PSP, change | —Not posted · NCT00649844 | —Trial running · NCT06961968 |
| Relapse (% of patients) | —Not posted · NCT00649844 | —Trial running · NCT06961968 |
PANSS total, change
- Clozapine
- —Not posted · NCT00649844
- Iloperidone (Fanapt)
- -12 vs -7.1−4.9 vs placeboNCT00254202
1 other result
- 1.1 vs 12.4 NCT01291511
CGI-S, change
- Clozapine
- —Not posted · NCT00649844
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
PANSS response
- Clozapine
- —Not posted · NCT00649844
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
PSP, change
- Clozapine
- —Not posted · NCT00649844
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
Relapse (% of patients)
- Clozapine
- —Not posted · NCT00649844
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Clozapine: 3 of 4 rows · Iloperidone (Fanapt): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Clozapine | Iloperidone (Fanapt) |
|---|---|---|
| Dropout rate | 41.7%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results0% NCT00498550 · Phase 4 · registry result, not featured evidence 17.2% NCT02404155 · Phase na · registry result, not featured evidence | 34.6%b NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results51.3%Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 30.3%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 31.5%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence 18.8%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 12.5%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 13.3%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 6.7%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 6.7%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results— NCT00498550 · Phase 4 · registry result, not featured evidence — NCT02404155 · Phase na · registry result, not featured evidence | —b NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results14.5%Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 10.4%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 15%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 13%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results26.7% NCT00498550 · Phase 4 · registry result, not featured evidence 6.9% NCT02404155 · Phase na · registry result, not featured evidence | 0.7%b NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results—Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.3%Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 4%Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.3%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 2.7%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 14.3%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 7.1%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | a other-sialorrhea 43.5% weight gain 30.4% sedation 21.7% NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more resultsgastrointestinal disorder - other: hypersalivation 66.7% somnolence 60% weight gain 40% NCT00498550 · Phase 4 · registry result, not featured evidence salivation 68.2% sedation 52.9% malaise 52.6% NCT02404155 · Phase na · registry result, not featured evidence | b headache 20.3% (placebo 19.7%) dizziness 17% (placebo 7.5%) sedation 12.7% (placebo 8.2%) NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 18 more resultsdizziness 11.6% (placebo 2.7%) somnolence 8.3% (placebo 0%) dry mouth 6.8% (placebo 0%) NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 dizziness 2.6% (placebo 2.7%) headache 2% (placebo 3.3%) insomnia 2% (placebo 4.7%) NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 dry mouth 17.9% dizziness 17.5% somnolence 14.2% NCT01207414 · Phase 4 · registry result, not featured evidence dizziness 22.3% dry mouth 20.8% insomnia 9.6% NCT01207414 · Phase 4 · registry result, not featured evidence 625 mg injection site pain 66.7% injection site induration 60% injection site swelling 20% NCT01348100 · Phase 1/2 · registry result, not featured evidence 625 mg headache 20% nasal congestion 20% anxiety 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 500 mg injection site pain 60% injection site induration 26.7% injection site swelling 20% NCT01348100 · Phase 1/2 · registry result, not featured evidence 500 mg nasal congestion 33.3% constipation 13.3% somnolence 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg back pain 7.1% constipation 7.1% headache 7.1% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg insomnia 20% headache 13.3% somnolence 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg constipation 14.3% headache 14.3% anxiety 7.1% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg headache 33.3% insomnia 33.3% dyspepsia 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg injection site pain 53.3% headache 26.7% nasal congestion 26.7% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg nasal congestion 40% headache 26.7% oropharyngeal pain 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 125 mg pruritus 50% throat irritation 50% upper respiratory tract infection 50% NCT01348100 · Phase 1/2 · registry result, not featured evidence 125 mg constipation 50% agitation 0% akathisia 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence 50 mg blood creatine phosphokinase increased 50% agitation 0% akathisia 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence 50 mg dizziness 50% headache 50% agitation 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 21 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Clozapine
Iloperidone (Fanapt)
show 1 more result
show 1 more result
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Iloperidone (Fanapt)'s landscape